“…In this latter group, the disease is usually secondary to interstitial fibrosis or due to associated primary pulmonary hypertension. Very few cases of pulmonary hypertension have been documented as secondary to histologically proven pulmonary vasculitis [5][6][7], and the distinction between vasculitis and changes secondary to pulmonary hypertension of any cause can be problematic [8]. In the case reported here, rheumatoid arthritis was confirmed by a positive rheumatoid factor and synovial biopsy, although the rheumatoid disease was mild as judged by current articular involvement.…”
In patients with rheumatoid arthritis, dyspnoea should be investigated at an early stage, even in the absence of obvious pleural or interstitial lung disease.
“…In this latter group, the disease is usually secondary to interstitial fibrosis or due to associated primary pulmonary hypertension. Very few cases of pulmonary hypertension have been documented as secondary to histologically proven pulmonary vasculitis [5][6][7], and the distinction between vasculitis and changes secondary to pulmonary hypertension of any cause can be problematic [8]. In the case reported here, rheumatoid arthritis was confirmed by a positive rheumatoid factor and synovial biopsy, although the rheumatoid disease was mild as judged by current articular involvement.…”
In patients with rheumatoid arthritis, dyspnoea should be investigated at an early stage, even in the absence of obvious pleural or interstitial lung disease.
“…It is more
commonly seen in other CTDs such as scleroderma and systemic lupus
erythematosis. 58 The
most common form of vascular involvement in RA is rheumatoid vasculitis, which
is characterized pathologically by the presence of a destructive inflammatory
infiltrate within small and medium-sized blood vessel walls. This condition
carries significant morbidity and mortality, but primary involvement of the lung
is rare.…”
Section: Forms Of Lung Disease In Rheumatoid Arthritismentioning
“…In comparison to other CTD, our understanding of rheumatoid arthritis‐associated pulmonary arterial hypertension (RA‐PAH) comes from only a few observational studies and case reports, summarized in the http://onlinelibrary.wiley.com/doi/10.1111/resp.12464/suppinfo. One observational study screened 146 rheumatoid arthritis patients with echocardiography, and reported that 21% had a pulmonary artery pressure of >30 mm Hg .…”
Section: Introductionmentioning
confidence: 99%
“…Additionally pulmonary hypertension may be the consequence of rheumatoid lung disease (interstitial lung disease, or vasculitis of the pulmonary tree). There have been six reports that have focused on the histological features in these patients and concluded that the pulmonary arterial hypertension was a consequence of rheumatoid vasculitis . In contrast, a case report suggests that the pulmonary hypertension was related to a pulmonary vasculopathy of intimal and medial thickening resulting in luminal narrowing but without plexogenic lesions .…”
Section: Introductionmentioning
confidence: 99%
“…It has been reported that RA patients with underlying lung pathology develop pulmonary hypertension earlier; however, their mean survival time is greater than patients with idiopathic pulmonary arterial hypertension (IPAH) . Many reports indicate that RA‐PAH is fatal, yet one cohort study reported a 1‐year survival of 96% . Given this survival rate, it has been speculated that RA‐PAH may be more like IPAH than SSc‐PAH or SLE‐PAH .…”
Compared with IPAH patients, RA-PAH patients have an older age of onset and lower baseline mPAP. RA-PAH patients have comparable survival to IPAH patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.